A bipartisan coalition of 32 members of Congress is urging federal health officials to expedite ongoing reviews of psychedelic therapies.
“For many individuals, current treatment options remain insufficient, deepening an already urgent public health crisis,” the lawmakers, led by Reps. Jack Bergman (R-MI) and Lou Correa (D-CA), co-chairs of the Congressional Psychedelics Advancing Therapies Caucus, wrote in a letter to the head of the Food and Drug Administration (FDA). “As Members of the House of Representatives, we have heard from countless Veterans, clinicians, and families seeking evidence-based alternatives.”
The letter to FDA Commissioner Marty Makary says lawmakers are “encouraged” by his recent statement that psychedelic treatments are “a top priority for this FDA and this administration.”
FDA and the Department of Health and Human Services (HHS) last month announced steps that they say will help with “accelerating” therapeutic access to psychedelics for patients dealing with serious mental health conditions.
That move followed a psychedelics executive order that President Donald Trump signed.
The lawmakers’ new letter said they want FDA to pursue “‘an expeditious and rapid review’ of promising treatments, especially those that address urgent unmet needs in PTSD, traumatic brain injury, and other neuropsychiatric conditions”—but they also “understand and respect
Read full article on Marijuana Moment
